Bay City Capital invests $5 million in SynGen - MarketLine Financial Deals

Bay City Capital invests $5 million in SynGen

Bay City Capital invests $5 million in SynGen - MarketLine Financial Deals
Bay City Capital invests $5 million in SynGen
Published Apr 18, 2012
2 pages — Published Apr 18, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

SynGen, Inc., a regenerative medicine device company focused on the development of stem cell harvesting systems, has completed a $5 million Series A preferred stock financing.

  
Source:
Document ID
MA106758_120420
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Bay City Capital invests $5 million in SynGen" Apr 18, 2012. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Bay-City-Capital-invests-5-million-in-SynGen-2052-80456>
  
APA:
MarketLine Financial Deals. (2012). Bay City Capital invests $5 million in SynGen Apr 18, 2012. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Bay-City-Capital-invests-5-million-in-SynGen-2052-80456>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.